Design Therapeutics
DSGN
52 hedge funds and large institutions have $415M invested in Design Therapeutics in 2021 Q3 according to their latest regulatory filings, with 3 funds opening new positions, 23 increasing their positions, 11 reducing their positions, and 1 closing their positions.
200% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 1
109% more repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 11
4% more funds holding
Funds holding: 50 → 52 (+2)
0.8% more ownership
Funds ownership: 50.05% → 50.85% (+0.8%)
24% less capital invested
Capital invested by funds: $546M → $415M (-$131M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
+$10M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
+$1.99M |
| 3 |
TD Asset Management
Toronto,
Ontario, Canada
|
+$738K |
| 4 |
LGM
Logos Global Management
San Francisco,
California
|
+$665K |
| 5 |
Goldman Sachs
New York
|
+$566K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$3.91M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.96M |
| 3 |
BlackRock
New York
|
-$1.51M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$831K |
| 5 |
Northern Trust
Chicago,
Illinois
|
-$211K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Osaic Holdings
Scottsdale,
Arizona
| $2K | – | – | – |
|
|
SOW
52
State of Wyoming
Cheyenne,
Wyoming
| $1K | -$665 | -40 | -33% |
|
|
PCM
53
Pinz Capital Management
New York
| – | -$86K | -4,338 | Closed |
|
DSGN Hedge Fund Activity: Q3 2021 in Review
52 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Design Therapeutics (DSGN) for Q3 2021, worth a combined $415M — down 24% from $546M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new DSGN positions and 1 closed out — a net gain of 2 holders — while 23 added to existing stakes and 11 trimmed.
The largest buyer was EcoR1 Capital, adding an estimated $10M. The largest seller was Octagon Capital Advisors, cutting an estimated $3.91M.
- 52 institutional investors held Design Therapeutics (DSGN) as of Q3 2021, up from 50 in Q2 2021.
- Funds reported $415M of Design Therapeutics stock for Q3 2021, down 24% quarter-over-quarter.
- 3 funds opened new Design Therapeutics positions in Q3 2021 and 1 closed out, a net change of +2 holders.
- The largest Design Therapeutics buyer in Q3 2021 was EcoR1 Capital, an estimated $10M added.
- The largest Design Therapeutics seller in Q3 2021 was Octagon Capital Advisors, an estimated $3.91M sold.
Based on aggregated 13F filings for Q3 2021.